The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications.
Eur J Obstet Gynecol Reprod Biol
; 157(1): 63-6, 2011 Jul.
Article
in En
| MEDLINE
| ID: mdl-21530058
ABSTRACT
OBJECTIVES:
To prospectively evaluate the safety of metformin administration during pregnancy in a group of PCOS patients by assessing its effect on the prevalence of gestational complications and neonatal outcome. STUDYDESIGN:
Our prospective, single centre study included 98 pregnant women with PCOS treated with metformin throughout pregnancy and 110 normal pregnant controls. All PCOS patients were hyperinsulinemic and received metformin (1700-3000 mg/day) before conception and until 37 weeks' gestation.RESULTS:
Metformin treatment in the pregnant PCOS patients resulted in significant decrease in miscarriage rate (9.1% vs 20%; p<0.05), gestational diabetes (0 vs 13%; p<0.005), and gestational hypertension (0 vs 11%; p<0.005) and a non-significant decrease in pre-eclampsia (0 vs 3%; p=.24), compared to the control group. Mean neonatal Apgar score, weight and length were comparable between the two groups.CONCLUSIONS:
Continuing metformin therapy throughout pregnancy resulted in significant reduction in pregnancy complications with concomitant improved neonatal outcome, with no serious deleterious side effects.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Polycystic Ovary Syndrome
/
Pregnancy Complications
/
Hypoglycemic Agents
/
Metformin
Type of study:
Clinical_trials
/
Prevalence_studies
/
Risk_factors_studies
Limits:
Adult
/
Female
/
Humans
/
Pregnancy
Country/Region as subject:
Europa
Language:
En
Journal:
Eur J Obstet Gynecol Reprod Biol
Year:
2011
Document type:
Article
Affiliation country:
Italia